Literature DB >> 22438364

MR volumetric measurement of low rectal cancer helps predict tumor response and outcome after combined chemotherapy and radiation therapy.

Stephanie Nougaret1, Philippe Rouanet, Nicolas Molinari, Marie Ange Pierredon, Frederic Bibeau, David Azria, Claire Lemanski, Eric Assenat, Jacqueline Duffour, Marc Ychou, Caroline Reinhold, Benoit Gallix.   

Abstract

PURPOSE: To retrospectively determine whether magnetic resonance (MR) volumetry of rectal cancer is a reproducible method for predicting disease-free survival (DFS) in patients with locally advanced low or midrectal tumors who undergo combined chemotherapy and radiation therapy (CRT) before total mesorectal excision.
MATERIALS AND METHODS: The institutional review board does not require approval for the use of patient data obtained for an observational retrospective study. Fifty-eight patients were included in the study; 42 patients had low-lying tumors. Two radiologists independently measured tumor volumes before and after CRT with use of semiautomated software. The radiologists were blinded to the clinical information for each patient. The tumor volume reduction ratio, circumferential resection margin, T stage, and occurrence of downstaging were compared with the histopathologic response and DFS. The threshold of tumor volume reduction for predicting DFS was assessed with receiver operating characteristic curve analysis. DFS was estimated with the Kaplan-Meier method and compared between groups with the log-rank test.
RESULTS: The interobserver correlation coefficient between the two radiologists was 0.87 (95% confidence interval [CI]: 0.76, 0.93) for pre-CRT volumetry and 0.81 (95% CI: 0.74, 0.90) for post-CRT volumetry. A tumor volume reduction of at least 70% was significantly associated with good histologic regression (tumor regression grade [TRG], 3 or 4) (P <.0001) compared with a volume reduction rate of less than 70%. DFS was studied in 51 patients. The mean follow-up of survivors at the time of analysis was 52 months ± 20 (standard deviation). Patients with a volume reduction ratio of at least 70% had a higher DFS (P <.0001). Tumor volume reduction was an independent prognostic parameter in multivariate analysis for DFS (P = .003; 95% CI: 0.01, 0.4).
CONCLUSION: The results demonstrate that volumetric measurements are reliable markers of rectal cancer prognosis, enabling the prediction of DFS and TRG. The cutoff of 70% is an easy parameter to use as a surrogate for clinical response to predict both TRG and outcome.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22438364     DOI: 10.1148/radiol.12111263

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  27 in total

1.  The value of diffusion kurtosis magnetic resonance imaging for assessing treatment response of neoadjuvant chemoradiotherapy in locally advanced rectal cancer.

Authors:  Jing Yu; Qing Xu; Jia-Cheng Song; Yan Li; Xin Dai; Dong-Ya Huang; Ling Zhang; Yang Li; Hai-Bin Shi
Journal:  Eur Radiol       Date:  2016-09-08       Impact factor: 5.315

Review 2.  Current concepts in rectal cancer.

Authors:  James W Fleshman; Nathan Smallwood
Journal:  Clin Colon Rectal Surg       Date:  2015-03

3.  Accuracy and feasibility of estimated tumour volumetry in primary gastric gastrointestinal stromal tumours: validation using semiautomated technique in 127 patients.

Authors:  Sree Harsha Tirumani; Atul B Shinagare; Ailbhe C O'Neill; Mizuki Nishino; Michael H Rosenthal; Nikhil H Ramaiya
Journal:  Eur Radiol       Date:  2015-05-20       Impact factor: 5.315

4.  Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.

Authors:  M P Morelli; M J Overman; A Dasari; S M A Kazmi; T Mazard; E Vilar; V K Morris; M S Lee; D Herron; C Eng; J Morris; B K Kee; F Janku; F L Deaton; C Garrett; D Maru; F Diehl; P Angenendt; S Kopetz
Journal:  Ann Oncol       Date:  2015-01-26       Impact factor: 32.976

5.  MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancer.

Authors:  T Seierstad; K H Hole; K K Grøholt; S Dueland; A H Ree; K Flatmark; K R Redalen
Journal:  Br J Radiol       Date:  2015-04-22       Impact factor: 3.039

6.  Endometrial Cancer: Combined MR Volumetry and Diffusion-weighted Imaging for Assessment of Myometrial and Lymphovascular Invasion and Tumor Grade.

Authors:  Stephanie Nougaret; Caroline Reinhold; Shaza S Alsharif; Helen Addley; Jocelyne Arceneau; Nicolas Molinari; Boris Guiu; Evis Sala
Journal:  Radiology       Date:  2015-04-30       Impact factor: 11.105

Review 7.  Multidisciplinary management of rectal cancer: the OSTRICH.

Authors:  David W Dietz
Journal:  J Gastrointest Surg       Date:  2013-07-25       Impact factor: 3.452

Review 8.  Advances and challenges in treatment of locally advanced rectal cancer.

Authors:  J Joshua Smith; Julio Garcia-Aguilar
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

Review 9.  Volumetric analysis at abdominal CT: oncologic and non-oncologic applications.

Authors:  Virginia B Planz; Meghan G Lubner; Perry J Pickhardt
Journal:  Br J Radiol       Date:  2018-11-30       Impact factor: 3.039

10.  Pelvic MRI after induction chemotherapy and before long-course chemoradiation therapy for rectal cancer: What are the imaging findings?

Authors:  Marc J Gollub; Ivana Blazic; David D B Bates; Naomi Campbell; Andrea Knezevic; Mithat Gonen; Patricio Lynn; Martin R Weiser; Julio Garcia-Aguilar; Andreas M Hötker; Andrea Cercek; Leonard Saltz
Journal:  Eur Radiol       Date:  2018-10-02       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.